Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Adoptive Cell Therapy
Treatment miR-26a-EZH2
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type RNA
Signature miR-26a
Official Symbol NA
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description miR-26a silencing as a novel strategy to improve the efficacy of CTL-based cancer immunotherapy,we evaluated the efficacy of miR-26a as a target for T cell adoptive transfer immunotherapy
PMID 28123882
Title The tumor microenvironment disarms CD8<U+00A0>+<U+00A0>T lymphocyte function via a miR-26a-EZH2 axis